Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
about
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelTetrazine-based cycloadditions: application to pretargeted live cell imagingCombination Radioimmunotherapy Approaches and Quantification of Immuno-PETComparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft modelsHow the biotin–streptavidin interaction was made even stronger: investigation via crystallography and a chimaeric tetramerBispecific digoxigenin-binding antibodies for targeted payload deliveryStructure-based design and synthesis of a bivalent iminobiotin analog showing strong affinity toward a low immunogenic streptavidin mutantStructure-based design of a streptavidin mutant specific for an artificial biotin analogueTumor immunotargeting using innovative radionuclidesA pretargeting system for tumor PET imaging and radioimmunotherapyRadioimmunotherapy of human tumoursSingle domain antibodies: promising experimental and therapeutic tools in infection and immunityA systems approach for tumor pharmacokineticsPulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors.Designed auto-assembly of nanostreptabodies for rapid tissue-specific targeting in vivo.Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma.Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas.A modeling analysis of the effects of molecular size and binding affinity on tumor targeting.In Vivo Pretargeted Imaging of HER2 and TAG-72 Expression Using the HaloTag Enzyme.Facile method for the site-specific, covalent attachment of full-length IgG onto nanoparticlesPretargeted radioimmunotherapy for hematologic and other malignanciesSystemic radiotherapy can cure lymphoma: a paradigm for other malignancies?Chemically modified antibodies as diagnostic imaging agentsGD2-targeted immunotherapy and radioimmunotherapyNovel radiolabeled antibody conjugates.Glypican-3 targeting of liver cancer cells using multifunctional nanoparticlesEvaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapy.Cancer radioimmunotherapy.Harnessing the bioorthogonal inverse electron demand Diels-Alder cycloaddition for pretargeted PET imaging.Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules.IART (Intra-Operative Avidination for Radionuclide Therapy) for accelerated radiotherapy in breast cancer patients. Technical aspects and preliminary results of a phase II study with 90Y-labelled biotin.Multimodality imaging of coiled-coil mediated self-assembly in a "drug-free" therapeutic system.Bioorthogonal Oxime Ligation Mediated In Vivo Cancer Targeting.Dextran-conjugated vascular endothelial growth factor receptor antibody for in vivo melanoma xenografted mouse imaging.Radiolabelled monoclonal antibodies in the treatment of metastatic cancerClinical radionuclide therapy dosimetry: the quest for the "Holy Gray".Cancer Imaging and Therapy with Bispecific Antibody Pretargeting.
P2860
Q24629826-BD3EAD3D-3B32-4039-9F33-19C1AD682370Q24649861-A83BC0A8-07C5-4B34-9AEF-0123CC7DC10CQ26747546-16695E6C-924C-4149-A908-32F8FCBCE303Q27311386-60EDD1E6-ED67-44ED-A4A7-EC8447B40E57Q27666604-2703C261-50A2-495A-AEDF-A2288E3355A8Q27667652-02FF479B-E4C3-4281-BE39-3FE11096D963Q27697299-54BDC990-9A0C-4BC5-9754-38569453EC95Q27697883-C2AEC1F1-ABA3-40D7-B803-EC0032D4C17BQ28083230-91B63980-8C71-4370-A78E-093C3E7763C6Q28087820-96C4BA12-FACA-4AEB-B80B-48B7FD85B17BQ28088825-A28AB8AC-7551-41A7-88CF-D884FB25D9CCQ28248678-C046906B-19A7-4588-BFDE-094BB629701BQ28477077-B697AA1B-8C0D-419F-B0BA-BFA30316784CQ30426788-6300E691-2E04-4DF4-996D-5B3167ADB2F1Q30492713-33933DC5-130D-41B7-9C19-CF3FE8AF785AQ33301860-926369CD-6A8F-4F3C-8C77-3C83FBB9138AQ33379811-9E10EABA-CD96-40AE-878B-1FD7F75B3D5BQ33412585-DC80A075-ACC2-4E53-8845-343FED05A22CQ33645793-42360DF9-3BDE-4AA5-8354-03067E2E224BQ33645841-151E78C1-F116-4B54-AC00-840E453E7E17Q33835328-9A90158B-E338-430E-8FB5-EAC878A109A5Q33877207-D2E1B351-802B-4AAD-A4DC-446E072DEB04Q34079536-CD1CC175-EA61-45EC-8856-5EAC522AD357Q34113941-755DD5B6-2F19-4F90-87ED-7B5F2C9F7240Q34335207-E6371D56-8A6D-482E-BDA4-5A77B0AB6553Q34441433-D405DDFF-8B4D-4157-9F55-86DFB5F58468Q34625339-3CADF740-6582-455C-A4F9-EEF8929B0D59Q34631801-367C1867-F9FB-49A2-B047-D91785F8D002Q34675546-86EABD35-8525-4437-82D8-377C443A2BD6Q34731015-8C1182FF-4BD6-42F6-B33C-74CCAEE96E5FQ35070045-14E39D54-069F-4F46-99D6-9640842C2897Q35162177-1E2DB01B-8BCE-4AA0-BA5D-E23E51CB7D29Q35600809-9BB0718A-7028-48A1-904A-C427D0FC9EE1Q35602161-ED47A4C3-4312-48BB-8AA1-E071E6C5B9A0Q35611416-4A8865D3-529F-4618-BA10-D5CEDFE02FEFQ35801347-752E26F7-481C-482C-8BD0-75B94A022221Q35831897-BE56B026-BEA5-461D-94F6-28E89DE0EE61Q35840380-8854DA9A-4759-43DA-A0CB-DC57AC9AC2E8Q35880923-CBFF223F-74A1-4EA1-A936-910D474DF0C6Q36082355-536EAC54-0FC1-4E22-9C56-2E65A7CAE4BD
P2860
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
@ast
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
@en
type
label
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
@ast
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
@en
prefLabel
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
@ast
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
@en
P2093
P356
P1476
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy
@en
P2093
David M Goldenberg
Jean-François Chatal
Robert M Sharkey
P304
P356
10.1200/JCO.2005.03.8471
P407
P577
2005-12-27T00:00:00Z